Mohammadi Esmaeil, Yoosefi Moein, Shaker Elaheh, Shahmohamadi Elnaz, Ghasemi Erfan, Ahmadi Naser, Azadnajafabad Sina, Rashidi Mohammad-Mahdi, Rezaei Nazila, Koolaji Sogol, Dilmaghani-Marand Arezou, Fateh Sahar Mohammadi, Kazemi Ameneh, Haghshenas Rosa, Rezaei Negar
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, No. 10, Al-e-Ahmad and Chamran Highway intersection, 1411713136 Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2023 May 22;22(2):1095-1103. doi: 10.1007/s40200-023-01186-5. eCollection 2023 Dec.
While many studies have reported hypertension (HTN) and pre-hypertension (PHTN) in large geographic locations of Iran, information regarding district levels is missing. We aimed to examine inequalities in the prevalence of hypertension, prehypertension, anti-hypertensive coverage, awareness, and effective treatment of adults in districts of Iran.
We used 27,165 participants' data from the STEPS 2016 study in Iran. A small area estimation model was carried out to predict HTN in the 429 districts of Iran. HTN and PHTN were defined based on the American Heart Association Guideline. Awareness of being hypertensive, treatment coverage, and effective treatment were also estimated.
HTN's crude prevalence was estimated to be in the range of 11.5-42.2% in districts. About PHTN, it was estimated to be 19.9-56.1%. Moreover, for awareness, treatment coverage, and effective treatment crude estimates ranged from 24.3 to 79.9%, 9.1 - 64.6%, and 19.5 - 68.3%, respectively, indicating inequalities in the distribution of aforementioned variables in 429 districts of Iran. Overall, better conditions were detected in central geographical locations and in females.
The inequality of increased blood pressure disorder and related measures are high in districts of Iran and pave the way for policymakers and local health organizers to use the findings of this study to address the inequity of existing resources and improve HTN control.
The online version contains supplementary material available at 10.1007/s40200-023-01186-5.
尽管许多研究报告了伊朗广大地区的高血压（HTN）和高血压前期（PHTN）情况，但缺乏地区层面的信息。我们旨在研究伊朗各地区成年人高血压、高血压前期的患病率、抗高血压药物覆盖率、知晓率及有效治疗方面的不平等情况。
我们使用了来自伊朗2016年 STEPS 研究的27165名参与者的数据。采用小区域估计模型来预测伊朗429个地区的高血压情况。高血压和高血压前期根据美国心脏协会指南进行定义。还对高血压知晓率、治疗覆盖率及有效治疗情况进行了估计。
各地区高血压的粗患病率估计在11.5%至42.2%之间。关于高血压前期，估计为19.9%至56.1%。此外，知晓率、治疗覆盖率及有效治疗的粗估计值分别在24.3%至79.9%、9.1%至64.6%和19.5%至68.3%之间，这表明在伊朗的429个地区，上述变量的分布存在不平等。总体而言，中部地区和女性的情况较好。
伊朗各地区血压紊乱增加及相关措施的不平等程度较高，这为政策制定者和地方卫生组织者利用本研究结果解决现有资源的不平等问题及改善高血压控制铺平了道路。
在线版本包含可在10.1007/s40200-023-01186-5获取的补充材料。
